TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
TCBP Announces Transition from Nasdaq to OTC Markets
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
TCBP to Implement ADS Ratio Change
TCBP Announces H5N1 Proof of Concept Studies Intention
TCBP to Present at Sequire Investor Summit 2025
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
TCBP Provides Update on Acquisition Strategy and Current Targets
TCBP Issues 25% Stock Dividend
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
TCBP Responds to False Social Media Claim
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
TCBP Announces Site Opening of Guys and St. Thomas Hospital
TCBP to Present at the 2024 ThinkEquity Conference in NYC
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
TCBP Announces Dosing of 5 New Patients in ACHIEVE
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)
TC BioPharm Announces Closing of $2.0 Million Public Offering
Why Is TC BioPharm (TCBP) Stock Down 46% Today?
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
TCBP Announces Plan to Implement ADS Ratio Change
TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia
TCBP Announces Launch of Compassionate Use Program for TCB008
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
Why Is TC Biopharm (TCBP) Stock Up 51% Today?
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
Why Is TC Biopharm (TCBP) Stock Up 78% Today?
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
TCBP Adjourns General Meeting Until a Later Date
TCBP Announces Exercise of Series D Warrants For Cash
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"
TCBP Announces Shareholder Update Call on March 5th 2024
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial